Genmab A/S (NASDAQ:GMAB) Given New $40.00 Price Target at HC Wainwright

Genmab A/S (NASDAQ:GMAB) had its target price upped by HC Wainwright from $39.00 to $40.00 in a report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

GMAB has been the subject of a number of other reports. Morgan Stanley began coverage on shares of Genmab A/S in a report on Monday. They issued an “equal weight” rating and a $34.00 target price for the company. Wall Street Zen downgraded shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Jefferies Financial Group initiated coverage on shares of Genmab A/S in a research note on Tuesday. They set a “buy” rating and a $41.50 price objective for the company. Truist Financial restated a “buy” rating and issued a $48.00 target price (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Finally, Johnson Rice reaffirmed a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and an average price target of $41.30.

Genmab A/S Stock Down 2.8%

Shares of NASDAQ:GMAB opened at $29.16 on Wednesday. The firm has a 50 day moving average of $32.25 and a 200 day moving average of $29.87. The company has a market capitalization of $18.73 billion, a price-to-earnings ratio of 18.81, a price-to-earnings-growth ratio of 17.61 and a beta of 0.90. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $35.43.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Genmab A/S had a net margin of 25.89% and a return on equity of 17.67%. On average, sell-side analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Large investors have recently bought and sold shares of the company. CIBC Private Wealth Group LLC increased its holdings in Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after buying an additional 616 shares during the period. NewEdge Advisors LLC boosted its holdings in shares of Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after acquiring an additional 1,143 shares during the last quarter. Brown Brothers Harriman & Co. boosted its holdings in shares of Genmab A/S by 143.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after acquiring an additional 780 shares during the last quarter. Founders Capital Management increased its stake in shares of Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after acquiring an additional 400 shares during the period. Finally, Community Bank N.A. purchased a new position in shares of Genmab A/S during the third quarter worth $47,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S News Roundup

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Company announced a targeted share buy‑back to cover Restricted Stock Unit obligations (repurchase of up to 342,130 shares, max ~725m DKK), which reduces float and is typically supportive of the share price. Genmab Announces Initiation of Share Buy‑Back Program
• Positive Sentiment: Multiple broker actions: HC Wainwright raised its price target to $40 (buy), Jefferies started coverage with a $41.50 buy rating, and Morgan Stanley began coverage — all represent fresh institutional support and higher PTs versus current levels. HC Wainwright PT raise / coverage reports
• Positive Sentiment: Earnings/IR materials highlighted strong revenue growth and strategic expansion initiatives, which investors can view as positive for medium‑term fundamentals even though EPS missed (see negative item). Q4 2025 Earnings Highlights
• Neutral Sentiment: Genmab published its 2025 Annual Report and filed Form 20‑F with the U.S. SEC — useful for diligence and visibility into guidance/backlog but not an immediate price mover by itself. Genmab Publishes 2025 Annual Report Genmab Files Form 20‑F
• Neutral Sentiment: Company summoned its Annual General Meeting for March 19, 2026 (routine governance event; may include board elections shown in the notice). AGM Notice
• Negative Sentiment: Genmab missed Q4 EPS expectations — reported EPS was below consensus (company’s EPS print came in under analyst estimates), which is the primary near‑term negative catalyst pressuring the stock despite revenue roughly in line. Q4 2025 Earnings Report / Transcript

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.